ESSA Pharma's Speculative Buy Potential: Masofaniten Promise For Prostate Cancer [Seeking Alpha]
ESSA Pharma Inc. (EPIX)
Last essa pharma inc. earnings: 2/13 05:48 pm
Check Earnings Report
US:NASDAQ Investor Relations:
essapharma.com/investors
Company Research
Source: Seeking Alpha
Masofaniten has the potential to overcome resistance to other standard-of-care treatments, offering a more effective option for patients with resistant prostate cancer. The market opportunity for Masofaniten is substantial, with the antiandrogen therapy market generating approximately $9 billion in 2022. ESSA Pharma is in strong financial health, with $135.9 million in liquidity and no financial debt, providing a long cash runway. I rate ESSA Pharma a speculative "buy" due to Masofaniten's promising clinical data and strong financial health. ESSA Pharma Inc. NASDAQ: EPIX ) is a clinical-stage pharmaceutical company focused on developing therapies based on N-terminal Domain [NTD] inhibitors, known as Anitens, to disrupt the androgen receptor [AR] and stop prostate cancer growth. EPIX's leading drug is Masofaniten, which has shown Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
EPIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EPIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EPIX alerts
High impacting ESSA Pharma Inc. news events
Weekly update
A roundup of the hottest topics
EPIX
News
- ESSA Pharma to Present at the Jefferies Global Healthcare ConferencePR Newswire
- Insider Stock Buying Reaches US$709.0k On ESSA Pharma [Yahoo! Finance]Yahoo! Finance
- ESSA Pharma Inc. (NASDAQ: EPIX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $17.00 price target on the stock.MarketBeat
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 [Yahoo! Finance]Yahoo! Finance
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024PR Newswire
EPIX
Earnings
- 5/14/24 - Miss
EPIX
Sec Filings
- 5/14/24 - Form 8-K
- 5/14/24 - Form 10-Q
- 5/6/24 - Form 4
- EPIX's page on the SEC website